Iabetes, 57.8 were previously diagnosed with hypertension (usually long standing). The HbA1c value at baseline was 5.6 . Compared to the DREAM study patients were older, had more frequently hypertension and patients with cardiovascular disease were not excluded. Conclusion: Comparing the ADaPT design and baseline data to previous randomized controlled trial it can be acknowledged that AdaPT included patients with a high risk for diabetes development. Results are expected to be available in 2010. Data will be highly valuable for clinical practice due to the observational study design.Page 1 of(page number not for citation purposes)Cardiovascular Diabetology 2008, 7:http://www.cardiab.com/content/7/1/BackgroundHypertension is the leading cause of morbidity and mortality worldwide . The concomitant manifestation of type 2 diabetes mellitus leads to a substantial further increase in risk [2,3]. While about 50 of patients in German primary care were hypertensive in a recent cross-sectional survey, 12 of all patients had a co-manifestation of hypertension and diabetes . Not only hypertensive patients with diabetes, but also hypertensive patients without diabetes tend to be resistant to insulin stimulated glucose uptake and are hyperinsulinaemic compared with normotensive controls . About 20 of patients with hypertension will develop type 2 diabetes in a three year period  and new onset diabetes in treated hypertensive patients is not trivial as recent studies suggest [7,8]. The risk for subsequent cardiovascular (CV) disease in Hypothemycin patients with pre-diabetes is not different from those who had both hypertension and diabetes already at baseline . The adjusted relative risk of events PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27725455 was about 3-times higher in both previous and new onset diabetes compared to patients with hypertension but without diabetes .Antihypertensive drugs and new-onset diabetes The roles of antihypertensive agents and in particular those that inhibit the RAS in the acceleration or deceleration of diabetes manifestation have been discussed controversial and study results on this question are not consistent.-blockers, the calcium channel blocker amlodipine or placebo, respectively. In a large meta-analyis, Abuissa et al. calculated the average risk reduction in 6 of these trials using ACEi and 7 trials using ARBs. The reduction of new onset-diabetes PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/11166326 was 24 for ACEi, 23 for ARBs and 23 for the combined data-set . Furthermore a recent network meta-analysis of randomized controlled trials showed that while patients taking betablockers and diuretics show an increased incidence of diabetes, it is reduced in patients using ACEi or ARBs (Figure 1) [14,15]. Endpoint studies to elucidate the role of antihypertensive agents on new onset diabetes related morbidity and mortality are however scarce. The VALUE trial with valsartan was the only trial to include new-onset diabetes as a prespecified endpoint . Patients were normoglycemic, those with abnormal glucose values were excluded. While 16.4 of patients in the amlodipine arm (up to 10 mg) developed diabetes over a mean follow-up of 4.2 years, 13.1 developed such in the valsartan arm (up to 160 mg); p < 0.0001. The ASCOT-BPLA study, which was a randomised controlled trial of the prevention of CHD and other vascular events by BP and cholesterol lowering in a factorial study design, was prematurely stopped in December 2004 [17,18]. The study was designed to resolve whether newer antihypertensive strateg.